ICP-332 与安慰剂在中重度斑块状银屑病受试者中的疗效和安全性
一项随机、双盲、安慰剂对照、平行组2期临床研究,旨在评估ICP-332在中重度斑块状银屑病患者中的疗效、安全性、药代动力学和药效学
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Anhui
-
Wuhu、Anhui、中国、241001
- The Second Affiliated Hospital of Wannan Medical College
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100005
- Beijing Tongren Hospital, Affiliated to Capital Medical University
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400011
- Chongqing Traditional Chinese Medicine Hospital
-
-
Fujian
-
Fuzhou、Fujian、中国、350005
- Fujian Medical University First Affiliated Hospital
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510091
- Dermatology Hospital of Southern Medical University
-
Shenzhen、Guangdong、中国、518020
- Shenzhen People's Hospital
-
-
Hebei
-
Shijiazhuang、Hebei、中国、230601
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Luoyang、Henan、中国、450000
- The Second Affiliated Hospital of Henan University of Science and Technology
-
Zhengzhou、Henan、中国、471000
- Henan Provincial People's Hospital
-
-
Hubei
-
Jingzhou、Hubei、中国、434020
- Jingzhou Central Hospital
-
-
Hunan
-
Changsha、Hunan、中国、410008
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215002
- Suzhou Municipal Hospital
-
Zhenjiang、Jiangsu、中国、212001
- Affiliated Hospital of Jiangsu University
-
-
Shandong
-
Jinan、Shandong、中国、250012
- Qilu Hospital of Shandong University
-
Jinan、Shandong、中国、250022
- Shandong Provincial Hospital of Dermatology
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200040
- Huashan Hospital Affiliated to Fudan University
-
Shanghai、Shanghai Municipality、中国、200443
- Shanghai Dermatology Hospital
-
-
Sichuan
-
Chengdu、Sichuan、中国、610000
- Chengdu Second People's Hospital
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300120
- Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
-
-
Yunnan
-
Kunming、Yunnan、中国、650000
- The First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310006
- Hangzhou First People's Hospital
-
Hangzhou、Zhejiang、中国、310009
- Hangzhou Third People's Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
-
Male or female subjects aged ≥ 18 years and ≤ 70 years
-
A history of plaque psoriasis for ≥6 months at baseline
-
Meet the following three criteria:
- Psoriasis Area and Severity Index (PASI) score ≥12
- Static Physician's Global Assessment (sPGA) score ≥3
- Psoriasis affected Body Surface Area (BSA) ≥10%
-
The subject requires systemic treatment and/or phototherapy.
Exclusion Criteria:
- Diagnosed with non-plaque psoriasis.
- Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
- Presence of clinically serious, progressive, or uncontrolled disease.
- Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
- Pregnant or lactating women.
- The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ICP-332 剂量 A
|
ICP-332 will be administered as tablet for 12 weeks |
|
实验性的:ICP-332 剂量 B
|
ICP-332 will be administered as tablet for 12 weeks |
|
实验性的:ICP-332 剂量 C
|
ICP-332 will be administered as tablet for 12 weeks |
|
安慰剂比较:ICP-332 安慰剂
|
Placebo will be administered as tablet for 12 weeks |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
第12周时,中重度银屑病参与者中PASI评分改善75%(较基线降低)的患者百分比(PASI-75应答率)
大体时间:第1天至第85天
|
第1天至第85天
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Percentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)
大体时间:Day 1 to Day 85
|
Day 1 to Day 85
|
|
Percentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)
大体时间:Day 1 to Day 85
|
Day 1 to Day 85
|
|
Number of Participants With Adverse Events
大体时间:Day 1 to Day 113
|
Day 1 to Day 113
|
|
The peak concentration (Cmax)
大体时间:Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The time to peak (Tmax)
大体时间:Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The half-life (t1/2)
大体时间:Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The area under the blood concentration-time curve (AUC0-∞ and AUC0-t)
大体时间:Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
合作者和调查者
调查人员
- 首席研究员:Yuling Shi、Shanghai Dermatology Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ICP-CL-00603
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.